BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26616283)

  • 1. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
    Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
    Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
    Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
    Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
    Schnepp RW; Khurana P; Attiyeh EF; Raman P; Chodosh SE; Oldridge DA; Gagliardi ME; Conkrite KL; Asgharzadeh S; Seeger RC; Madison BB; Rustgi AK; Maris JM; Diskin SJ
    Cancer Cell; 2015 Nov; 28(5):599-609. PubMed ID: 26481147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AKT Regulates Mitotic Progression of Mammalian Cells by Phosphorylating MASTL, Leading to Protein Phosphatase 2A Inactivation.
    Reshi I; Nisa MU; Farooq U; Gillani SQ; Bhat SA; Sarwar Z; Nabi N; Fazili KM; Andrabi S
    Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.
    Álvarez-Fernández M; Sanz-Flores M; Sanz-Castillo B; Salazar-Roa M; Partida D; Zapatero-Solana E; Ali HR; Manchado E; Lowe S; VanArsdale T; Shields D; Caldas C; Quintela-Fandino M; Malumbres M
    Cell Death Differ; 2018 May; 25(5):828-840. PubMed ID: 29229993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
    Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
    Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MASTL: A novel therapeutic target for Cancer Malignancy.
    Fatima I; Singh AB; Dhawan P
    Cancer Med; 2020 Sep; 9(17):6322-6329. PubMed ID: 32692487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of the Greatwall Kinase Weakens the Spindle Assembly Checkpoint.
    Diril MK; Bisteau X; Kitagawa M; Caldez MJ; Wee S; Gunaratne J; Lee SH; Kaldis P
    PLoS Genet; 2016 Sep; 12(9):e1006310. PubMed ID: 27631493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MASTL is the human orthologue of Greatwall kinase that facilitates mitotic entry, anaphase and cytokinesis.
    Voets E; Wolthuis RM
    Cell Cycle; 2010 Sep; 9(17):3591-601. PubMed ID: 20818157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.
    Meehan M; Parthasarathi L; Moran N; Jefferies CA; Foley N; Lazzari E; Murphy D; Ryan J; Ortiz B; Fabius AW; Chan TA; Stallings RL
    Mol Cancer; 2012 Feb; 11():6. PubMed ID: 22305495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Greatwall kinase in release of mouse oocytes from diplotene arrest.
    Zhao X; Yu D; Feng C; Deng X; Wu D; Jin M; Wang E; Wang X; Yu B
    Dev Growth Differ; 2014 Dec; 56(9):669-78. PubMed ID: 25472593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high-risk neuroblastoma.
    Ooi WF; Re A; Sidarovich V; Canella V; Arseni N; Adami V; Guarguaglini G; Giubettini M; Scaruffi P; Stigliani S; Lavia P; Tonini GP; Quattrone A
    Genes Chromosomes Cancer; 2012 Jun; 51(6):545-56. PubMed ID: 22337647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma.
    Ramani P; Nash R; Rogers CA
    Histopathology; 2015 Feb; 66(3):370-9. PubMed ID: 25297850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.